BioMarin Pharmaceutical — Oct 29, 2024 release

• During the quarter, BioMarin reaffirmed long-term guidance and outlook previously provided at Investor Day on September 4, 2024, targeting: ◦ Approximately $4 billion in Total Revenues in 2027; ◦ 40% Non-GAAP Operating Margin (1) starting in 2026 and growing to the low- to mid-40% range over time; ◦ More than $1.25 billion operating cash flow per year starting in 2027; ◦ Mid-teen compound annual growth rate (CAGR) for total revenues through 2034; and ◦ Treatments for Skeletal Conditions to represent a greater than $5 billion revenue opportunity over time. (1) Refer to Non-GAAP Information beginning on page 10 of this press release for a complete discussion of the company’s Non-GAAP financial information. Reconciliation of forward-looking Non-GAAP financial measures to the comparable information reported under U.S. GAAP is not available. Refer to Forward-Looking Non-GAAP Financial Information on page 5 for further information. 3 Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 % Change 2024 2023 % Change Total Revenues $746 $581 28% $2,107 $1,773 19% Net Product Revenues by Product: VOXZOGO $190 $123 54% $527 $324 63% VIMIZIM $178 $159 12% $549 $526 4% NAGLAZYME $132 $109 21% $370 $322 15% PALYNZIQ $91 $79 15% $255 $216 18% ALDURAZYME $71 $14 407% $145 $89 63% BRINEURA $37 $41 (10)% $121 $118 3% KUVAN $28 $43 (35)% $93 $144 (35)% ROCTAVIAN $7 $1 600% $16 $1 1,500% GAAP Net Income $106 $40 16